Heterocyclic Compounds

Matches 451 - 500 out of 12,018	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >

Document	Document Title
WO/2022/216900A2	SYNTHESIS OF RAPAMYCIN ANALOG COMPOUNDS The present disclosure relates to novel methods for preparing rapamycin analog compounds, as well as to related intermediates useful in such methods.
WO/2022/207699A1	ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES The present invention pertains to enzyme-triggered self-reacting arm compounds, chemical intermediates used for preparing such compounds and uses thereof, specifically in prodrug design and conjugation technologies. The present invention...
WO/2022/207752A1	PHARMACEUTICAL COMPOUND A compound comprising the formula (I), wherein each X1 is independently selected from C, N, O and S; each Y is independently selected from C and N; Z1 is independently selected from C and N; each X1 may independently be unsubstituted, or...
WO/2022/211498A1	NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present invention provides a novel compound and an organic light-emitting device using same.
WO/2022/212194A1	KHK INHIBITORS Compounds of formula (I), wherein the variable substituents are defined herein.
WO/2022/211314A1	HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
WO/2022/212815A1	QUINAZOLINE-4(3H)-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 Described are 6-aryl quinazolin-4(3H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treat...
WO/2022/206964A1	PRMT5 INHIBITOR AND USE THEREOF Provided are a compound represented by formula (I), a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or co-crystal, or a pharmaceutical composition comprising same, and a use t...
WO/2022/211500A1	NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME The present invention provides an organic light-emitting device, which comprises, in an emissive layer and/or an electron blocking layer, a compound represented by chemical formula 1, and thus enables efficiency, driving voltage and/or l...
WO/2022/204544A1	MACROCYCLIC EGFR INHIBITORS FOR THE TREATMENT OF CANCER Described herein are macrocyclic compounds of Formula (I), which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula ...
WO/2022/199611A1	HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF Provided is a heterocycle substituted ketone derivative, the structure of which is as shown in formula (I). Further provided are a pharmaceutically acceptable salt of the derivative, a stereoisomer thereof, a pharmaceutical composition a...
WO/2022/200433A1	IMIDAZO[1,2-B]PYRIDAZINE BASED TRICYCLIC COMPOUNDS AS INHIBITORS OF HASPIN AND THERAPEUTIC USES THEREOF The present invention relates to a group of compounds with a tricyclic core based on imidazo[1,2-b]pyridazine of formula (I) which are inhibitors of HASPIN, whose activity is required for the proliferation of certain tumoral cells, so th...
WO/2022/199587A1	PYRIMIDINE HETEROCYCLIC COMPOUND AND APPLICATION THEREOF A pyrimidine heterocyclic compound and an application thereof, in particular, relating to a compound as represented by formula (II) or a pharmaceutically acceptable salt thereof.
WO/2022/199576A1	METHOD FOR PREPARING HIGH-PURITY MIDOSTAURIN A method for preparing midostaurin, the method comprising the following step: reacting a compound as represented by formula N-1 with benzoyl chloride in a pyrrolidone solvent in the presence of a base (such as an inorganic base), thereby...
WO/2022/200505A1	IMIDAZO-, OXAZO-, THIAZO- PYRIDINIUM COMPOUNDS AS FLUORESCENT PROBES The present invention relates to novel compounds of general formula (I); wherein X-, Y, and R1 R5 and n have the meanings given in the description and claims, process for preparing these compounds and use thereof.
WO/2022/198315A1	METHODS OF TREATING MENTAL AND/OR MOOD DISORDERS USING 2-BROMO-LSD ALONE OR IN COMBINATION WITH A MTOR INHIBITOR Methods for treatment of mental and/or mood disorders in a subject are disclosed. The methods comprise administration to a subject in need thereof an effective amount of 2-bromo-LSD and/or a mTOR inhibitor. Also disclosed are pharmaceuti...
WO/2022/194399A1	MACROCYCLES AS CFTR MODULATORS The present invention relates to macrocyclic compounds of Formula (I) wherein Ar1, Ar2, R1, R2, R3, R4, and X are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharm...
WO/2022/194248A1	CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF A CTLA-4 small molecule degradation agent and an application thereof. The CTLA-4 small molecule degradation agent comprises a compound having the structure represented by formula I or a pharmaceutically acceptable salt, an ester, a deute...
WO/2022/198112A1	INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE Bifunctional compounds, of formula PTM-L-CLM, where the CLM is of formulae al-a4, the PTM f formula PTM-IA and L is a ligand. These compounds act on several diseases via agonism on LRRK2 and cereblon E3 ubiquitin ligase.
WO/2022/194976A1	MACROCYCLIC LRRK2 KINASE INHIBITORS Compounds of formula (I) are useful as LRRK2 kinase inhibitors.
WO/2022/197761A1	PLASMA KALLIKREIN INHIBITORS The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit f...
WO/2022/194096A1	ESTROGEN RECEPTOR ANTAGONIST A compound represented by formula (I) or a stereoisomer, tautomer or pharmaceutical salt thereof, and use thereof in preparation of a medicament for preventing and/or treating estrogen receptor (ER)-related diseases or disorders.
WO/2022/194245A1	PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF A pyrimidine-fused cyclic compound having an inhibitory effect on a KRAS gene mutation, or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, a pharmaceutical composition containing the compound, and the use th...
WO/2022/195454A1	PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the...
WO/2022/192648A1	METHODS FOR CONTROLLING FLEA AND TICK INFESTATIONS IN A MAMMAL An active material is orally administered to a mammal substantially daily, which eventually increases the mammal's blood concentration of the active material to an amount effective to control a flea and/or tick infestation of the mammal....
WO/2022/192145A1	MAP4K1 INHIBITORS One embodiment of the disclosureis a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat...
WO/2022/188729A1	FUSED RING DERIVATIVES USEFUL AS KRAS G12D INHIBITORS The disclosure relates to a KRAS G12D inhibitors of formula (I) or formula (IV), a composition containing the inhibitor and the use thereof.
WO/2022/189191A1	TRICYCLIC PESTICIDAL COMPOUNDS The invention relates to compounds of formula (I) wherein the variables are as defined in the specification. It also relates to the use of compounds of formula (I) as an agrochemical pesticide; to pesticidal mixtures comprising compounds...
WO/2022/189387A1	TRICYCLIC PYRIDINES AS CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS The invention relates to pharmaceutical compounds of formula (I) and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of cyclin-depen...
WO/2022/187423A1	CEREBLON LIGANDS The present disclosure provides compounds of Formula (I), wherein A, A1, A2, A3, R3, Z and Z1 are as defined in the specification, and the salts and solvates thereof. The present disclosure also relates to uses of the compounds as cerebl...
WO/2022/186133A1	FUSED HETEROCYCLE COMPOUND HAVING SULFONAMIDE GROUP OR SALT THEREOF, AGRICULTURAL/HORTICULTURAL PESTICIDE AND EXTERNAL OR INTERNAL PARASITE CONTROLLING AGENT FOR ANIMALS CONTAINING SAID COMPOUND OR SALT THEREOF, AND METHOD OF USE THEREFOR In agricultural and horticultural crop production, there is still a great amount of damage due to pests and the like. Thus, the present invention addresses the problem of providing a novel agricultural/horticultural pesticide from the vi...
WO/2022/184103A1	TRICYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE THEREOF The present invention relates to the field of pharmaceutical chemistry, and relates to a tricyclic compound and a pharmaceutical composition and use thereof. The compound is a compound as represented by formula I, has good PARP7 inhibito...
WO/2022/184152A1	FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF A compound having HPK1 inhibitory activity as shown in formula (IA) or (IC), and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and use of sam...
WO/2022/186221A1	NOVEL TETRAHYDROISOQUINOLINE ALKALOID COMPOUND CONTAINING MACROCYCLE [Problem] To provide: a novel tetrahydroisoquinoline (THIQ) alkaloid compound having a macrocyclic structure; an intermediate of the compound; and a method for producing the compound. [Solution] Provided is a compound represented by form...
WO/2022/182845A1	MACROCYCLES AND THEIR USE The present disclosure relates to macrocyclic compounds, pharmaceutical compositions containing macrocyclic compounds, and methods of using macrocyclic compounds to treat disease, such as cancer.
WO/2022/177840A1	TETRACYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS The present invention relates to Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising a...
WO/2022/174834A1	DISACCHARIDE LINKER, DISACCHARIDE-SMALL MOLECULE DRUG CONJUGATE AND SUGAR CHAIN FIXED-POINT ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present application relates to a disaccharide linker, a disaccharide-small molecule drug conjugate and a sugar chain fixed-point antibody-drug conjugate, and a preparation method therefor and the use thereof. The structure of the dis...
WO/2022/175747A1	TYK2 INHIBITORS AND USES THEREOF Described herein are triazole compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions...
WO/2022/175745A1	TYK2 INHIBITORS AND USES THEREOF Described herein are compounds that are TYK2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, disease...
WO/2022/171265A1	MODULATORS OF COMPLEX I The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I).
WO/2022/173678A1	TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF Provided herein are tetracyclic oxazepinyl compounds useful in the treatment on cancers.
WO/2022/171111A1	HETEROARYL-FUSED BICYCLIC COMPOUND AS RIP1-KINASE INHIBITORS AND USES THEREOF A compound of formula I below as RIP1 kinase inhibitor and uses thereof.
WO/2022/171198A1	INFLUENZA VIRUS INHIBITOR AND USE THEREOF Provided are compounds represented by formula (I), formula (II), formula (III) and formula (IV) as influenza virus replication inhibitors and the use thereof in the preparation of a medicament for preventing or treating influenza.
WO/2022/171110A1	FUSED TRICYCLIC COMPOUNDS AS RIP1-KINASE INHIBITORS AND USES THEREOF A compound of formula I below as RIP1 kinase inhibitor and uses thereof.
WO/2022/171139A1	MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF A compound as represented by formula (1), or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, isotope marker, isomer or prodrug thereof. Also provided are a pharmaceutical composition comprising the compound and...
WO/2022/166799A1	FUSED TRICYCLIC CYCLIN-DEPENDENT KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Provided are a fused tricyclic cyclin-dependent kinase inhibitor, and a preparation method therefor and a pharmaceutical use thereof. In particular, the structure of the fused tricyclic cyclin-dependent kinase inhibitor is shown in formu...
WO/2022/166749A1	TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Disclosed are a triheterocyclic compound, a preparation method therefor, and an application thereof. Specifically, provided is a triheterocyclic compound as represented by formula IA or a pharmaceutically acceptable salt thereof. The tri...
WO/2022/169948A1	TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and m...
WO/2022/166991A1	INDOLINE COMPOUND An indoline compound. Specifically disclosed is an application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.
WO/2022/169755A1	SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF The present application discloses novel compounds of formula (I), pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a co...

Matches 451 - 500 out of 12,018	< 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 >